OlympiA, a phase III, double-blinded, randomized controlled trial, evaluated the role of olaparib as adjuvant therapy in 1836 patients with HER2-negative early breast cancer and gBRCAMUT pathogenic or likely pathogenic variants who had received local treatment and neoadjuvant or adjuvant chemotherapy [52]. Here, ERBB2 is linked to breast cancer.